89bio Inc Total Liabilities
89bio Inc total liabilities. Based on the latest financial reports, 89bio Inc (ETNB) has total liabilities worth $81.75 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ETNB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of 89bio Inc (2018–2024)
Total liabilities of 89bio Inc from 2018 to 2024. This chart illustrates how 89bio Inc's total liabilities have evolved over time, based on quarterly financial data.
89bio Inc Competitors by Total Liabilities
The table below lists competitors of 89bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bonesupport Holding AB
ST:BONEX
|
Sweden | Skr169.24 Million |
|
Fabege AB
ST:FABG
|
Sweden | Skr45.61 Billion |
|
Vera Therapeutics Inc
NASDAQ:VERA
|
USA | $122.04 Million |
|
Nuscale Power Corp
NYSE:SMR
|
USA | $35.54 Million |
|
WaFd, Inc.
NASDAQ:WAFD
|
USA | $24.57 Billion |
|
Korea Gas Corporation
KO:036460
|
Korea | ₩41.80 Trillion |
|
Anadolu Efes Biracilik ve Malt Sanayi AS
IS:AEFES
|
Turkey | TL201.02 Billion |
|
Hilltop Holdings Inc
NYSE:HTH
|
USA | $13.39 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down 89bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is 89bio Inc's balance sheet.
Liquidity & Leverage Metrics
89bio Inc Total Liabilities Ratios Explained
89bio Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 89bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 89bio Inc (2018–2024)
The table below shows the annual total liabilities of 89bio Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $77.90 Million | +29.91% |
| 2023-12-31 | $59.96 Million | +33.27% |
| 2022-12-31 | $44.99 Million | +23.38% |
| 2021-12-31 | $36.47 Million | +349.46% |
| 2020-12-31 | $8.11 Million | +44.64% |
| 2019-12-31 | $5.61 Million | -79.55% |
| 2018-12-31 | $27.43 Million | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more